Talphera

Talphera R&D per Employee

The R&D Spending per Employee of Talphera (TLPH) as of Nov 22, 2026 is 317,526.32 USD. In the previous year, R&D Spending per Employee was 353,578.95 USD — a change of -10.20% (lower).

R&D per Employee

317,526.32USD

YoY

-10.20%

Last updated:

R&D Spending per Employee of Talphera is 2025 317,526.32 USD. R&D Spending per Employee of Talphera was 2024 353,578.95 USD. It decreases by -10.20% lower compared to the previous year.

The Talphera R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
691,421.05 USD
Jan 1, 2019
245,315.79 USD
Jan 1, 2020
211,421.05 USD
Jan 1, 2021
128,157.89 USD
Jan 1, 2022
89,157.89 USD
Jan 1, 2023
291,894.74 USD
Jan 1, 2024
353,578.95 USD
Jan 1, 2025
317,526.32 USD
The Talphera R&D per Employee history
YEARR&D per EmployeeYoY
317,526.32USD-10.20%
353,578.95USD+21.13%
291,894.74USD+227.39%
89,157.89USD-30.43%
128,157.89USD-39.38%
211,421.05USD-13.82%
245,315.79USD-64.52%
691,421.05USD-32.31%
1.02 MUSD-9.31%
1.13 MUSD-4.83%
1.18 MUSD-8.29%
1.29 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

R&D Spending per Employee of Talphera is 317,526.32 USD in 2025.

R&D Spending per Employee of Talphera changed from 353,578.95 USD to 317,526.32 USD, representing a -10.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Talphera since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Talphera

All Key Metrics — Talphera